Highlights

  • Cambium Bio is advancing Elate Ocular for moderate to severe dry eye disease.
  • The FDA agreed that a single pivotal trial can support a potential Marketing application if endpoints are met.
  • The company secured funding to support the planned Phase 3 CAMOMILE-2 study.
  • Clinical outcomes and regulatory progress remain key future milestones.

Cambium Bio Limited (ASX:CMB) is a Sydney-based regenerative medicine company developing biological therapies. The company is advancing Elate Ocular, an investigational treatment for dry eye disease, with its current focus centred on progressing through clinical development and regulatory requirements.

Elate Ocular and dry eye disease

Cambium Bio's lead programme, Elate Ocular, is a topical eye treatment derived from human platelet lysate. The therapy is being developed for moderate to severe dry eye disease, a condition where existing treatment Options may not address the needs of all patients.

The pivotal trial pathway

The company has received agreement from the US Food and Drug Administration that a single pivotal Phase 3 trial may support a potential Biologics License Application if the study meets required endpoints. The planned CAMOMILE-2 study is designed to enrol 475 patients.

Funding and development considerations

Cambium Bio secured approximately A$10.85 million to support the clinical programme. The company remains dependent on successful trial execution, funding availability and regulatory outcomes.

Key Insights

Cambium Bio's progress highlights the importance of regulatory planning and clinical evidence in biotechnology development. The single pivotal trial pathway provides a defined milestone structure, while treatment approval remains dependent on future clinical and regulatory outcomes.